Related references
Note: Only part of the references are listed.LAG3's Enigmatic Mechanism of Action
Colin G. Graydon et al.
FRONTIERS IN IMMUNOLOGY (2021)
The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
Elly Marcq et al.
CANCERS (2021)
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Michael Dougan et al.
CELL (2021)
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
Riyao Yang et al.
NATURE COMMUNICATIONS (2021)
Therapeutic Targeting of checkpoint Receptors within the DnAM1 Axis
Zoya Alteber et al.
CANCER DISCOVERY (2021)
Biomarkers of Checkpoint Inhibitor Induced Immune-Related Adverse Events-A Comprehensive Review
Josefien W. Hommes et al.
FRONTIERS IN ONCOLOGY (2021)
Enhanced Efficacy of Simultaneous PD-1 and PD-L1 Immune Checkpoint Blockade in High-Grade Serous Ovarian Cancer
Changxin Wan et al.
CANCER RESEARCH (2021)
The yin and yang of co-inhibitory receptors: toward anti-tumor immunity without autoimmunity
Alexandra Schnell et al.
CELL RESEARCH (2020)
CD96 functions as a co-stimulatory receptor to enhance CD8+ T cell activation and effector responses
Eugene Y. Chiang et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2020)
Recalling the Biological Significance of Immune Checkpoints on NK Cells: A Chance to Overcome LAG3, PD1, and CTLA4 Inhibitory Pathways by Adoptive NK Cell Transfer?
Pilar M. Lanuza et al.
FRONTIERS IN IMMUNOLOGY (2020)
NK Cell-Based Immune Checkpoint Inhibition
Muhammad Khan et al.
FRONTIERS IN IMMUNOLOGY (2020)
Checkpoint molecules coordinately restrain hyperactivated effector T cells in the tumor microenvironment
Min Yang et al.
ONCOIMMUNOLOGY (2020)
CD244 represents a new therapeutic target in head and neck squamous cell carcinoma
Laura Agresta et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)
VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy
Xing Huang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2020)
Multi-omics prediction of immune-related adverse events during checkpoint immunotherapy
Ying Jing et al.
NATURE COMMUNICATIONS (2020)
CD200-CD200R Pathway in the Regulation of Tumor Immune Microenvironment and Immunotherapy
Jin-Qing Liu et al.
TUMOR MICROENVIRONMENT: SIGNALING PATHWAYS, PT A (2020)
Dendritic cells in cancer immunology and immunotherapy
Stefanie K. Wculek et al.
NATURE REVIEWS IMMUNOLOGY (2020)
Co-inhibitory T cell receptor KLRG1: human cancer expression and efficacy of neutralization in murine cancer models
Steven A. Greenberg et al.
Oncotarget (2019)
CD96 Is an Immune Checkpoint That Regulates CD8+ T-cell Antitumor Function
Deepak Mittal et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Adverse Events Following Cancer Immunotheraoy: Obstacles and Opportunities
Kristen E. Pauken et al.
TRENDS IN IMMUNOLOGY (2019)
Quantitative Interactomics in Primary T Cells Provides a Rationale for Concomitant PD-1 and BTLA Coinhibitor Blockade in Cancer Immunotherapy
Javier Celis-Gutierrez et al.
CELL REPORTS (2019)
DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy
Beatriz Sanchez-Correa et al.
CANCERS (2019)
Preclinical Development of the Anti-LAG-3 Antibody REGN3767: Characterization and Activity in Combination with the Anti-PD-1 Antibody Cemiplimab in Human PD-1xLAG-3-Knockin Mice
Elena Burova et al.
MOLECULAR CANCER THERAPEUTICS (2019)
VISTA is an acidic pH-selective ligand for PSGL-1
Robert J. Johnston et al.
NATURE (2019)
The Role Of PD-1/PD-L1 Axis In Treg Development And Function: Implications For Cancer Immunotherapy
Jiajing Cai et al.
ONCOTARGETS AND THERAPY (2019)
BTLA blockade enhances Cancer therapy by inhibiting IL-6/IL-10-induced CD19high B lymphocytes
Yu-Li Chen et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
2B4 and CD48: A powerful couple of the immune system
Hadas Pahima et al.
CLINICAL IMMUNOLOGY (2019)
PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8+ T-cell Function
Sarah Whelan et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity
Benjamin Murter et al.
CANCER IMMUNOLOGY RESEARCH (2019)
Dual PD1/LAG3 immune checkpoint blockade limits tumor development in a murine model of chronic lymphocytic leukemia
Marina Wierz et al.
BLOOD (2018)
Mechanisms of resistance to immune checkpoint inhibitors
Russell W. Jenkins et al.
BRITISH JOURNAL OF CANCER (2018)
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Kimio Yonesaka et al.
CLINICAL CANCER RESEARCH (2018)
Blockade of the checkpoint receptor TIGIT prevents NK cell exhaustion and elicits potent anti-tumor immunity
Qing Zhang et al.
NATURE IMMUNOLOGY (2018)
Understanding the tumor immune microenvironment (TIME) for effective therapy
Mikhail Binnewies et al.
NATURE MEDICINE (2018)
SIRPα-CD47 Immune Checkpoint Blockade in Anticancer Therapy
Andre Veillette et al.
TRENDS IN IMMUNOLOGY (2018)
IL21 Therapy Combined with PD-1 and Tim-3 Blockade Provides Enhanced NK Cell Antitumor Activity against MHC Class I-Deficient Tumors
Hyungseok Seo et al.
CANCER IMMUNOLOGY RESEARCH (2018)
Coming of Age: CD96 Emerges as Modulator of Immune Responses
Hristo Georgiev et al.
FRONTIERS IN IMMUNOLOGY (2018)
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Alice L. Hung et al.
ONCOIMMUNOLOGY (2018)
Small-Molecule Immune Checkpoint Inhibitors Targeting PD-1/PD-L1 and Other Emerging Checkpoint Pathways
Pottayil G. Sasikumar et al.
BIODRUGS (2018)
Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells
Michal A. Stanczak et al.
JOURNAL OF CLINICAL INVESTIGATION (2018)
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells
Pascale Andre et al.
CELL (2018)
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12
Christopher S. Garris et al.
IMMUNITY (2018)
Ig-Like Transcript 2 (ILT2) Blockade and Lenalidomide Restore NK Cell Function in Chronic Lymphocytic Leukemia
Monica Villa-Alvarez et al.
FRONTIERS IN IMMUNOLOGY (2018)
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration
Ayman Oweida et al.
CLINICAL CANCER RESEARCH (2018)
Combination Therapy with Anti-PD-1, Anti-TIM-3, and Focal Radiation Results in Regression of Murine Gliomas
Jennifer E. Kim et al.
CLINICAL CANCER RESEARCH (2017)
High NKG2A expression contributes to NK cell exhaustion and predicts a poor prognosis of patients with liver cancer
Cheng Sun et al.
ONCOIMMUNOLOGY (2017)
Identification of a subset of human natural killer cells expressing high levels of programmed death 1: A phenotypic and functional characterization
Silvia Pesce et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
PD-L1 interacts with CD80 to regulate graft-versus-leukemia activity of donor CD8+ T cells
Xiong Ni et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
T-cell immunoglobulin mucin 3 blockade drives an antitumor immune response in head and neck cancer
Jian-Feng Liu et al.
MOLECULAR ONCOLOGY (2017)
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Enfu Hui et al.
SCIENCE (2017)
Role of tumor microenvironment in tumorigenesis
Maonan Wang et al.
JOURNAL OF CANCER (2017)
PD-1 Blockade Promotes Emerging Checkpoint Inhibitors in Enhancing T Cell Responses to Allogeneic Dendritic Cells
Carmen Stecher et al.
FRONTIERS IN IMMUNOLOGY (2017)
Restoration of Natural Killer Cell Antimetastatic Activity by IL12 and Checkpoint Blockade
Isabel Ohs et al.
CANCER RESEARCH (2017)
Blockade of CD112R and TIGIT signaling sensitizes human natural killer cell functions
Feng Xu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Loredana Ruggeri et al.
HAEMATOLOGICA (2016)
Effects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cells
Loredana Ruggeri et al.
HAEMATOLOGICA (2016)
Constitutively expressed Siglec-9 inhibits LPS-induced CCR7, but enhances IL-4-induced CD200R expression in human macrophages
Hiroshi Higuchi et al.
BIOSCIENCE BIOTECHNOLOGY AND BIOCHEMISTRY (2016)
The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
Priti S. Hegde et al.
CLINICAL CANCER RESEARCH (2016)
Immunomodulatory Functions of BTLA and HVEM Govern Induction of Extrathymic Regulatory T Cells and Tolerance by Dendritic Cells
Andrew Jones et al.
IMMUNITY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Leonid Cherkassky et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Identification of CD112R as a novel checkpoint for human T cells
Yuwen Zhu et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2016)
KIR 2D (L1, L3, L4, S4) and KIR 3DL1 protein expression in non-small cell lung cancer
Yayi He et al.
ONCOTARGET (2016)
Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium
Eileen S. Kim et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Increased Tim-3 expression in peripheral NK cells predicts a poorer prognosis and Tim-3 blockade improves NK cell-mediated cytotoxicity in human lung adenocarcinoma
Liyun Xu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2015)
CD47 blockade triggers T cell-mediated destruction of immunogenic tumors
Xiaojuan Liu et al.
NATURE MEDICINE (2015)
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Jun Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Neoantigens in cancer immunotherapy
Ton N. Schumacher et al.
SCIENCE (2015)
LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model
Ruea-Yea Huang et al.
ONCOTARGET (2015)
Molecular and cellular insights into T cell exhaustion
E. John Wherry et al.
NATURE REVIEWS IMMUNOLOGY (2015)
Perforin and granzymes: function, dysfunction and human pathology
Ilia Voskoboinik et al.
NATURE REVIEWS IMMUNOLOGY (2015)
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8+ T Cell Effector Function
Robert J. Johnston et al.
CANCER CELL (2014)
VISTA Is an Immune Checkpoint Molecule for Human T Cells
J. Louise Lines et al.
CANCER RESEARCH (2014)
VISTA Regulates the Development of Protective Antitumor Immunity
Isabelle Le Mercier et al.
CANCER RESEARCH (2014)
Enhanced suppressor function of TIM-3+FoxP3+ regulatory T cells
Anne-Sophie Gautron et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2014)
Differential CTLA-4 expression in human CD4+ versus CD8+ T cells is associated with increased NFAT1 and inhibition of CD4+ proliferation
D. V. Chan et al.
GENES AND IMMUNITY (2014)
T-cell Immunoglobulin and ITIM Domain (TIGIT) Receptor/Poliovirus Receptor (PVR) Ligand Engagement Suppresses Interferon-γ Production of Natural Killer Cells via β-Arrestin 2-mediated Negative Signaling
Man Li et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2014)
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance
Camilla Jandus et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Immunoregulation of Dendritic Cells by the Receptor T cell Ig and Mucin Protein-3 via Bruton's Tyrosine Kinase and c-Src
Neeraj Maurya et al.
JOURNAL OF IMMUNOLOGY (2014)
Comparison of Immunity in Mice Cured of Primary/Metastatic Growth of EMT6 or 4THM Breast Cancer by Chemotherapy or Immunotherapy
Reginald M. Gorczynski et al.
PLOS ONE (2014)
PD-1 Expression on Peripheral Blood Cells Increases with Stage in Renal Cell Carcinoma Patients and Is Rapidly Reduced after Surgical Tumor Resection
Alexander W. MacFarlane et al.
CANCER IMMUNOLOGY RESEARCH (2014)
The Dual Role of HLA-G in Cancer
Nathalie Rouas-Freiss et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2014)
Intratumoral regulatory T cells upregulate immunosuppressive molecules in head and neck cancer patients
H-B Jie et al.
BRITISH JOURNAL OF CANCER (2013)
Anti-PD-1 Antibody Therapy Potently Enhances the Eradication of Established Tumors By Gene-Modified T Cells
Liza B. John et al.
CLINICAL CANCER RESEARCH (2013)
Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions
Yan Wu et al.
HEPATOLOGY (2013)
CTLA-4 controls the thymic development of both conventional and regulatory T cells through modulation of the TCR repertoire
Johan Verhagen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Structures of CD200/CD200 Receptor Family and Implications for Topology, Regulation, and Evolution
Deborah Hatherley et al.
STRUCTURE (2013)
TIM3+FOXP3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer
Kaori Sakuishi et al.
ONCOIMMUNOLOGY (2013)
CD48 as a novel molecular target for antibody therapy in multiple myeloma
Naoki Hosen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1
Julien Fourcade et al.
CANCER RESEARCH (2012)
Costimulatory Protein 4IgB7H3 Drives the Malignant Phenotype of Glioblastoma by Mediating Immune Escape and Invasiveness
Dieter Lemke et al.
CLINICAL CANCER RESEARCH (2012)
Engagement of Siglec-7 Receptor Induces a Pro-Inflammatory Response Selectively in Monocytes
Stefania Varchetta et al.
PLOS ONE (2012)
The blockade of immune checkpoints in cancer immunotherapy
Drew M. Pardoll
NATURE REVIEWS CANCER (2012)
Cutting Edge: TIGIT Has T Cell-Intrinsic Inhibitory Functions
Nicole Joller et al.
JOURNAL OF IMMUNOLOGY (2011)
CD200 expression suppresses natural killer cell function and directly inhibits patient anti-tumor response in acute myeloid leukemia
S. J. Coles et al.
LEUKEMIA (2011)
Trans-Endocytosis of CD80 and CD86: A Molecular Basis for the Cell-Extrinsic Function of CTLA-4
Omar S. Qureshi et al.
SCIENCE (2011)
Immunomodulation of monocyte-derived dendrite cells through ligation of tumor-produced mucins to Siglec-9
Mariko Ohta et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
The NK receptor KLRG1 is dispensable for virus-induced NK and CD8+ T-cell differentiation and function in vivo
Carsten Gruendemann et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2010)
LAG-3 Expression Defines a Subset of CD4+CD25highFoxp3+ Regulatory T Cells That Are Expanded at Tumor Sites
Chiara Camisaschi et al.
JOURNAL OF IMMUNOLOGY (2010)
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
Michael A. Curran et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
Mojgan Ahmadzadeh et al.
BLOOD (2009)
Clinical importance of B7-H3 expression in human pancreatic cancer
I. Yamato et al.
BRITISH JOURNAL OF CANCER (2009)
SHP-2 Expression Negatively Regulates NK Cell Function
Amanda K. Purdy et al.
JOURNAL OF IMMUNOLOGY (2009)
T Cell Intrinsic Heterodimeric Complexes between HVEM and BTLA Determine Receptivity to the Surrounding Microenvironment
Timothy C. Cheung et al.
JOURNAL OF IMMUNOLOGY (2009)
Disruption of T cell suppression in chronic lymphocytic leukemia by CD200 blockade
Christian P. Pallasch et al.
LEUKEMIA RESEARCH (2009)
The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells
Xin Yu et al.
NATURE IMMUNOLOGY (2009)
Negative signaling by inhibitory receptors: the NK cell paradigm
Eric O. Long
IMMUNOLOGICAL REVIEWS (2008)
CTLA-4 control over Foxp3+ regulatory T cell function
Kajsa Wing et al.
SCIENCE (2008)
Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines
Min Jung Kim et al.
TUMOR BIOLOGY (2008)
NK cells at the interface between innate and adaptive immunity
A. Moretta et al.
CELL DEATH AND DIFFERENTIATION (2008)
Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses
Manish J. Butte et al.
IMMUNITY (2007)
KLRG1 binds cadherins and preferentially associates with SHIP-1
Marlowe S. Tessmer et al.
INTERNATIONAL IMMUNOLOGY (2007)
A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9
Philipp S. van de Weyer et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity
Ryungsa Kim et al.
IMMUNOLOGY (2006)
Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity
M Ito et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Cutting edge:: Identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1
C Gründemann et al.
JOURNAL OF IMMUNOLOGY (2006)
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
C Zhu et al.
NATURE IMMUNOLOGY (2005)
Targeted disruption of the 2B4 gene in mice reveals an in vivo role of 2B4 (CD244) in the rejection of B16 melanoma cells
SV Vaidya et al.
JOURNAL OF IMMUNOLOGY (2005)
Murine B7-H3 is a negative regulator of T cells
DVR Prasad et al.
JOURNAL OF IMMUNOLOGY (2004)
Molecular mechanisms of CD200 inhibition of mast cell activation
SL Zhang et al.
JOURNAL OF IMMUNOLOGY (2004)
Recruitment of C-terminal Src kinase by the leukocyte inhibitory receptor CD85j
J Sayós et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9
Y Ikehara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2
M Gavrieli et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Expression of CD94-NKG2A inhibitory receptor is restricted to a subset of CD8+ T cells
VM Braud et al.
TRENDS IN IMMUNOLOGY (2003)
Cutting edge: Inhibitory functions of the killer cell lectin-like receptor G1 molecule during the activation of mouse NK cells
SH Robbins et al.
JOURNAL OF IMMUNOLOGY (2002)
Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants
L Ruggeri et al.
SCIENCE (2002)
Inhibition of natural killer cell activation signals by killer cell immunoglobulin-like receptors (CD158)
EO Long et al.
IMMUNOLOGICAL REVIEWS (2001)
B7-H3:: A costimulatory molecule for T cell activation and IFN-γ production
AI Chapoval et al.
NATURE IMMUNOLOGY (2001)
KIR expression on self-reactive CD8+ T cells is controlled by T-cell receptor engagement
B Huard et al.
NATURE (2000)
Share Paper
